The 3 Things That Matter for Moderna Now

Since hitting their peak in late 2021, Moderna's (NASDAQ: MRNA) shares are down by more than 90%. The biotech company gained recognition by developing one of the leading coronavirus vaccines on the market, but its revenue and earnings subsequently plummeted as the pandemic waned.Can Moderna rebound and surpass its previous highs? Whether it can do so will depend on several key developments investors should pay close attention to. Let's consider three.Moderna continues to generate decent annual revenue from its coronavirus vaccine, Spikevax. In the second quarter, the company reported $114 million in sales from this product. It's essential to note, though, that Spikevax generates most of its revenue during the second half of the year. Moderna expects its total revenue to be between $1.5 billion and $2.2 billion this year, with the majority of this revenue coming from Spikevax. Most medicines or vaccines never generate more than $1 billion in annual revenue, so Moderna's performance in this market is still noteworthy.Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool